Table 3.
Cost effectiveness of different treatment pathways for advanced hepatocellular carcinoma
| Regimen | Treatments: 1. = 1st-line 2. = 2nd-line | Average QALY | Average cost, USD | CER | Toxicity rate | Average survival, months | 12-Month survival rate |
|---|---|---|---|---|---|---|---|
| A | 1. sorafenib 2. regorafenib |
0.549 | 145,018.96 | 264,185.19 | 0.459 | 8.62 | 0.515 |
| B | 1. sorafenib 2. cabozantinib |
0.556 | 148,669.18 | 267,527.62 | 0.461 | 8.70 | 0.534 |
| C | 1. sorafenib 2. pembrolizumab |
0.566 | 128,903.33 | 227,741.03 | 0.386 | 8.71 | 0.535 |
| D | 1. sorafenib 2. nivolumab |
0.573 | 136,397.20 | 238,070.23 | 0.372 | 9.09 | 0.597 |
| E | 1. lenvatinib 2. regorafenib |
0.597 | 152,919.47 | 256,008.73 | 0.424 | 9.12 | 0.574 |
| F | 1. lenvatinib 2. cabozantinib |
0.602 | 155,529.84 | 258,460.32 | 0.426 | 9.18 | 0.587 |
| G | 1. lenvatinib 2. pembrolizumab |
0.610 | 140,419.08 | 230,371.17 | 0.369 | 9.19 | 0.590 |
| H | 1. lenvatinib 2. nivolumab |
0.615 | 146,352.27 | 237,899.15 | 0.358 | 9.48 | 0.638 |
QALY, quality-adjusted life year; CER, cost effectiveness ratio.